文献速递浆细胞疾病

达雷妥尤单抗治疗高危复发难治多发性骨髓瘤:1q21获得/扩增与GEP70状态对结局的不良影响

Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
PubMed 文献 · Br J Haematol · 2019-12-09

该研究纳入81例接受CD38抗体达雷妥尤单抗治疗的复发/难治多发性骨髓瘤患者,评估1q21获得/扩增与GEP70风险评分的预后价值。

要点

  • 达雷妥尤单抗治疗前GEP70高风险与复发/难治骨髓瘤不良生存显著相关。
  • 无1q21获得且GEP70低风险者中位PFS和OS未达到,提示该标志物组合可用于风险分层。

核心结论

  • 1q21获得和GEP70是达雷妥尤单抗治疗的复发/难治多发性骨髓瘤患者强有力的预后标志物。
  • 根据这些标志物分类为高风险的患者治疗反应持续时间更短。

研究设计与样本

  • 研究纳入81例接受达雷妥尤单抗治疗的复发/难治多发性骨髓瘤患者。
  • 1q21采用荧光原位杂交在初诊时检测,GEP70评分在初诊时及达雷妥尤单抗治疗前分别测定。

主要发现

  • 无1q21获得且GEP70低风险患者的中位PFS和OS未达到。

关键数值与推荐

  • 1q21获得采用荧光原位杂交在初诊时检测。
  • GEP70风险评分在初诊时和达雷妥尤单抗治疗前分别测定。

临床怎么用

  • 对接受达雷妥尤单抗治疗的复发/难治多发性骨髓瘤患者,可考虑在治疗前检测GEP70风险评分以辅助预后分层。
  • 1q21获得状态可结合治疗前GEP70评分识别达雷妥尤单抗治疗反应持续时间可能较短的高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gain of chromosome 1q21 and the gene expression-based GEP70 risk score are established prognostic markers for newly diagnosed Multiple Myeloma (MM) patients. Here we addressed the prognostic impact of these two markers in 81 relapsed/refractory (RR) MM patients treated with the CD38-antibody daratumumab. Fluorescence in situ hybridization for 1q21 was performed at initial presentation, while the GEP70 score was determined at initial presentation and prior to daratumumab treatment. While the GEP70 at initial presentation showed a trend for inferior survival, the GEP70 collected prior to daratumumab treatment was significantly associated with poor outcome (P < 0·05). The worst outcome was seen for patients who were positive for gain(1q) and classified as GEP70 high risk prior to daratumumab [progression-free (PFS) and overall survival (OS) of 0·3 years (95% CI: 0·15-1·4 years) and 0·8 years (95% CI: 0·5-1·9 years) respectively], while the median PFS and OS were not reached by patients without gain(1q) and GEP70 low-risk status. In conclusion, gain(1q) and the GEP70 are powerful prognostic markers for RR MM patients treated with daratumumab, and patients classified as high risk according to these markers experience shorter treatment response.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mohan M, Weinhold N, Schinke C, et al. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. Br J Haematol. 2019. PMID: 31820442. doi:10.1111/bjh.16292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。